Drug Profile
HYC 750
Alternative Names: HYC750; ORC-HYC750Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator University of Alberta
- Developer Orcrist Bio
- Class
- Mechanism of Action Stem cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Anaemia; Neutropenia
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Anaemia(Chemotherapy-induced) in Canada
- 04 Nov 2017 No recent reports of development identified for preclinical development in Neutropenia(Chemotherapy-induced) in Canada
- 06 Apr 2009 The European Competent Authority in Spain approves a phase I trial of HYC 750 in healthy volunteers